2 Neil Woodford stocks I wouldn’t touch with a bargepole

G A Chester explains why he’s steering clear of these two Neil Woodford-backed stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Neil Woodford-backed Circassia Pharmaceuticals (LSE: CIR) raised £191m at 310p a share and had a market capitalisation of £600m when it listed on the stock market in 2014. It was lossmaking but had high hopes for a range of allergy treatments it was developing.

In 2015, it raised a further £263m to fund two acquisitions. One gave it infrastructure in key markets for the commercial launch of its allergy treatments (“once approved”) and the other gave it a pipeline of complementary products in the respiratory diseases space.

Unfortunately, its flagship cat allergy treatment failed a Phase III study in 2016. And after its house dust mite treatment also failed, it abandoned its entire allergy programme. It was left with its respiratory products and a deal for certain commercial rights to two AstraZeneca products. The shares are now trading below 100p and its market cap is about half that of its flotation.

Testing patience

Circassia was at one time a top 10 holding in Woodford’s Patient Capital Trust but he shifted it into his Equity Income fund last August at a time when he was increasing Patient Capital’s exposure to riskier unquoted stocks. Not that Circassia isn’t risky. It’s never made a profit and analysts are expecting an £86m pre-tax loss on revenue of £47m when it posts its results for 2017. And losses are forecast to continue for the foreseeable future.

Due to the uninspiring history and lossmaking outlook, I view Circassia as a stock to avoid at this stage. I also note that a hedge fund (Mangrove Partners) has increased its position significantly over the last 12 months, from below 2% to 5.42%. I’m not privy to Mangrove’s thesis on Circassia but it tells us: “We focus on companies that are executing a flawed business plan or strategy, engaging in fraud, or capitalizing on a fad.”

Frankenstein creation

Another Woodford-backed company on my list of stocks to avoid is BCA Marketplace (LSE: BCA). Not all companies grow from small acorns. Some £1bn businesses are constructed within the blink of an eye. Team an entrepreneurial executive with a corporate finance house, and heavyweight backing from City fund managers and banks, and a new industry giant can be conjured by buying up a clutch of existing businesses.

BCA is one such company. An AIM cash shell in 2014, it’s now a £1.4bn FTSE 250-listed group. It’s a major player in the secondhand vehicle industry, with businesses across the market. I’m not keen on Frankenstein creations of this type. They’re often launched in a ‘hot’ sector and if the sector is cyclical, there’s every risk of overpaying for assets at the top of the cycle. I fear this could be the case with BCA.

The group reported rising revenue and profit in its half-year results in November but as my Foolish friend Roland Head noted, the car market looks like it could be heading for a downturn. BCA’s net debt of £287m may not seem too onerous but I see considerable risk behind the face of the balance sheet (and off it) in the event of a downturn. A forecast P/E of over 16 at a share price of 167p offers an insufficient margin of safety for the risk, in my view. I also note that four hedge funds have disclosed short positions in the stock, totalling 2.35%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Road 2025 to 2032 new year direction concept
Investing Articles

Here’s the latest 12-month Nvidia stock price growth forecast

Is Nvidia stock still worth considering as it quietly creeps towards another record high? Ben McPoland considers a few key…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

This dividend stock offers a high 13.5% yield and could be 60% undervalued

An income stock with a very high yield, and with technology growth prospects, will carry risk too -- but it…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Up 79% in 5 years, this UK travel stock is still a Strong Buy, according to brokers

Our writer thinks Hostelworld (LSE:HSW) is an interesting small-cap UK stock that might be worth considering for an ISA today.

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

Looking for cheap growth shares? Here’s one I think investors MUST consider right now

Market jitters over the global economy mean many top growth shares continue to trade cheaply. Here's one of my favourite…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Dividend Shares

Buying 500 Vodafone shares could generate a passive income of…

Jon Smith explains why Vodafone stock still offers him an above-average dividend yield despite the recent dividend cut.

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing For Beginners

3 ways I’m trying to protect my FTSE stock portfolio from rising geopolitical tensions

Jon Smith talks through different measures, including buying gold-related FTSE stocks, that can help his portfolio ride out volatility.

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

As oil prices tick upwards, should investors buy BP shares?

Dr James Fox takes a closer look at BP shares as oil prices push higher on the back of heightened…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

I love this grocer… so, should I buy Ocado shares?

Ocado shares are not looking healthy. The stock has truly been through the mill in recent years but is there…

Read more »